These CART.BiTEs were shown to be effective when administered intracranially to mice bearing brain tumors, with the CART.BiTEs directly killing EGFRvIII+ tumor cells, while also redirecting endogenous T cells to kill WT EGFR+ tumor cells. The gene discussed is EGFR; the disease is neoplasm.